Login to Your Account

Clinic Roundup

Tuesday, August 30, 2011
Curacyte AG, of Munich, Germany, terminated its Phase III PHOENIX trial of PHP/Hemoximer for catecholamine-resistant distributive shock following a planned interim analysis in which an independent data monitoring board unanimously recommended stopping the trial. The analysis considered data from two-thirds of the study patients and showed a higher number of deaths in the treatment arm than in the placebo arm.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription